Released Aug 12, 2014, after the close
10-Q filed Aug 12, 2014, 43 days after period end · 0001104659-14-059898
Q2 2014 · 10-Q
Revenue—
Net Income-$6.07M-$6.07M N/M vs Q2 2013N/M vs Q1 2014
EPS Diluted-$0.30-$0.30 N/M vs Q2 2013N/M vs Q1 2014
Operating Income-$6,040,000N/M
Operating Cash Flowderived-$5,489,000N/M
Free Cash Flowderived-$5,515,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2014 | Q2 2013 | Q2 2012 |
|---|---|---|---|
| Revenue | — | $290.00K | $1.08M |
| Net Income | -$6.07M | -$5.53M | -$2.74M |
| EPS Diluted | -$0.30 | -$4.46 | -$2.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR